Clarametyx Biosciences Expands Scientific Advisory Board

Four experts in biologic therapeutics and vaccines join to guide anti-biofilm pipeline development.

Jan. 28, 2026 at 8:31am

Got story updates? Submit your updates here. ›

Clarametyx Biosciences, a clinical-stage biotech company developing immune-enabling medicines to address biofilm-driven chronic respiratory disease, has appointed four new experts to its Scientific Advisory Board. Drs. Bruce Forrest, George Siber, Obadiah Plante, and David Zarley will provide guidance as Clarametyx accelerates development of its anti-biofilm technology pipeline, including its lead asset CMTX-101, which recently reported positive top-line data.

Why it matters

Chronic respiratory diseases driven by bacterial biofilms are a major unmet medical need. Clarametyx's innovative approach to targeting biofilms could lead to new treatment options for patients. Strengthening the company's Scientific Advisory Board with world-class experts in biologics and vaccines development signals Clarametyx's commitment to advancing its pipeline and maximizing the potential of its anti-biofilm technologies.

The details

The four new Scientific Advisory Board members bring decades of experience in pharmaceutical development, biopharmaceuticals, vaccines, and infectious disease research. They will provide critical external validation and insights to enhance Clarametyx's ongoing development efforts for its anti-biofilm therapeutic pipeline, including its lead asset CMTX-101 which recently reported positive top-line data from a Phase 2a study in cystic fibrosis-related, biofilm-driven infections.

  • Clarametyx announced the new SAB appointments on January 28, 2026.

The players

Clarametyx Biosciences

A clinical-stage biotechnology company developing immune-enabling medicines to address biofilm-driven chronic respiratory disease.

Bruce Forrest, MD

An expert with over 35 years of global leadership in pharmaceutical development, specializing in biopharmaceuticals and vaccines.

George Siber, MD

An infectious disease-trained physician with 50 years of experience in developing vaccines and antibody products, previously serving as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer).

Obadiah Plante, PhD

An internationally recognized leader in biotech, vaccines and infectious disease research, previously leading vaccine and immunotherapy research at Moderna.

David Zarley, PhD

An expert with over 30 years of experience in the research, development and manufacturing of viral, bacterial and therapeutic vaccines, previously serving as Vice President for Program Management at Pfizer Vaccine Research and Development.

Got photos? Submit your photos here. ›

What they’re saying

“On the heels of our positive topline trial data, we continue to build momentum with our anti-biofilm therapeutic pipeline and have bold aspirations to enrich this pipeline with complementary programs that can address persistent unmet medical needs. The evolution of our Scientific Advisory Board is a critical step to enable us to fully explore the clinical potential reach of these approaches.”

— David V. Richards, Chief Executive Officer

The takeaway

Clarametyx is strengthening its scientific expertise and advisory capacity as it advances its innovative anti-biofilm technology pipeline to address the significant unmet need in chronic respiratory diseases driven by bacterial biofilms.